47 results about "Eosinophil" patented technology

Described herein are methods of managing eosinophilic esophagitis (EoE) in a patient, wherein the patient records the number of episodes of dysphagia on a patient report outcome (PRO) questionnaire prior to and during the course of treatment. While on treatment, the number of episodes of dysphagia are reduced, as reported on the PRO questionnaire. In some embodiments, the esophageal eosinophils are counted before or after treatment, or both. In some embodiments, esophageal eosinophils counts are not correlated with a reduction in the episodes of dysphagia.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

The invention discloses an acidophilic protein recognition method, device and equipment. The method comprises the following steps: constructing a data set which takes acidophilic protein as a positive sample and takes thermophilic, halophilic and basophilic protein as a negative sample, and preprocessing the data set; dividing the data set into a training set and a test set according to a preset proportion; performing feature coding on the protein sequence in the data set by using a pre-trained ESM C model, extracting deep semantic features, and generating high-dimensional embedded representation; learning high-dimensional embedding representation through an adversarial network DCGAN-GP to perform data enhancement, and obtaining a pseudo-negative class sample; combining the pseudo negative sample and the data set to obtain a combined set, and inputting the combined set into a lightweight shared sparse hybrid expert model for training to obtain a trained lightweight shared sparse hybrid expert model; and inputting a to-be-identified protein sequence into the trained lightweight shared sparse hybrid expert model to obtain an acidophilic protein prediction result. According to the method, efficient prediction of the acidophilic protein can be realized.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The invention discloses a construction method of an animal model for combined induction and exacerbation of asthma. The method comprises the following steps: injecting ovalbumin or dermatophagoides pteronyssinus extract into an intraperitoneal cavity for sensitization; aerosol inhalation of allergen is carried out for airway re-exposure; in the aggravating stage, pathogenic microorganisms such as pseudomonas aeruginosa, aspergillus fumigatus or respiratory syncytial virus are given and exposed to 500 mu g / m PM2.5 aerosol; lung tissue and bronchoalveolar lavage fluid are then detected. The established model shows that the airway resistance is obviously enhanced and persistent, the mucous thrombus formation rate is greater than 50%, the smooth muscle is obviously thickened, and the model is accompanied by eosinophilic granulocyte and neutrophil infiltration and high expression of various inflammatory factors. The model is good in stability and high in repeatability, can truly simulate clinical asthma acute exacerbation and steroid insensitive characteristics, and provides a platform for asthma mechanism research and new drug screening.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The application belongs to the technical field of medicine, and discloses application of a perilla leaf extract in preparation of a medicine for treating and / or preventing asthma-chronic obstructive pulmonary disease (ACO). The perilla leaf extract has a significant curative effect in treating and / or preventing ACO disease, can significantly improve aggregation of inflammatory cells in the lung of an ACO mouse and generation levels of inflammatory factors, and improve lung function and pathological changes of lung tissue inflammation; in addition, the perilla leaf extract can significantly inhibit generation of neutrophil inflammatory factors TNF-alpha, IL-6 and IL-1beta, and inhibit generation of an eosinophil inflammatory factor TNF-alpha.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present disclosure relates, in part, to compositions comprising anti-CD39 antibodies for use in methods for reducing eosinophil cells or function and / or treating diseases or conditions associated with unwanted eosinophil activity.

The present invention provides compounds for use in the treatment of mild-to-moderate asthma with a high risk of asthma exacerbations, wherein said compounds binds bind the cytokines IL-13 and TSLP. High risk of asthma exacerbations is assessed according to specific biomarkers, in particular elevated levels of fractional exhaled nitric oxide (FeNO) and an elevated eosinophil count in blood.

This invention belongs to the field of pharmaceutical technology. Addressing the problem that current TCM treatments for allergic rhinitis-asthma syndrome primarily rely on literature review and the experience of renowned practitioners, lacking clinically validated and fixed-composition TCM formulas, this invention proposes a TCM composition, a TCM preparation, its preparation method, and its application. The TCM composition provided by this invention is made from the following raw materials in parts by weight: Bupleurum chinense 3-10 parts, Angelica sinensis 6-15 parts, Paeonia lactiflora 6-15 parts, Magnolia biondii 6-15 parts, Cicadae periostracum 3-12 parts, Perilla frutescens 6-15 parts, Citrus reticulata 6-15 parts, Fritillaria cirrhosa 2-10 parts, Astragalus membranaceus 10-30 parts, Atractylodes macrocephala 10-30 parts, Saposhnikovia divaricata 6-12 parts, and Glycyrrhiza uralensis 3-12 parts. This invention can effectively improve the disease control level of CARAS patients, increase asthma control test scores, significantly reduce allergic rhinitis control symptom scores, significantly improve quality of life, and significantly alleviate clinical symptoms. Specifically, it promotes the recovery of disease and lung function by regulating immunity, increasing IFN-γ levels, reducing eosinophil infiltration, and improving chronic airway inflammation.

Disclosed are a sample analysis apparatus and method which include: obtaining a first light signal by irradiating a first test sample from blood and a first-channel reagent to differentiate neutrophils, eosinophils, lymphocytes, and monocytes; obtaining a second light signal from a second test sample from the blood and a second-channel reagent; counting the nucleated red blood cells and lymphocytes based on the second light signal; determining accuracy of the lymphocyte result from the first test sample; and if inaccurate, correcting the lymphocyte result based on the lymphocyte result of the second test sample.

Provided herein are compounds of Formula (I-A), or salts thereof, including any isomer of the above, wherein the variables are as defined herein. Such compounds can be useful in methods of treating an eosinophilic condition, disease, or disorder. Such compounds can be administered orally. Compositions described herein can be used to reduce eosinophil effector function.

The invention relates to the field of biological detection, in particular to a marker and application thereof in construction of a preeclampsia prediction model. The invention provides a marker, which comprises a red blood cell index and an inflammation marker; the red blood cell indexes comprise red blood cell count, hemoglobin, hematocrit, average red blood cell volume, average red blood cell hemoglobin and red blood cell distribution width variable coefficient; the inflammatory markers comprise leukocytes, neutrophils, lymphocytes, monocytes, platelets, eosinophils, platelet hematocrit, a systemic inflammatory response index and a systemic immune inflammatory index. The invention develops an efficient and easily available preeclampsia prediction tool, realizes early recognition and management of preeclampsia, and finally reduces maternal and infant complications.

The present disclosure provides a method of treating eosinophilic COPD and / or eosinophilic inflammatory responses of eosinophilic COPD in a subject in need thereof. The method comprises orally administering to the subject a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof. The treating eosinophilic COPD can comprise reducing the rate of COPD exacerbation, reducing a mucus plug score, reducing the rate of hospitalizations due to exacerbations, reducing the rate of oral / parenteral steroid and / or antibiotic use for treatment of COPD, changing the level of one or more biomarkers associated with eosinophilic chronic obstructive pulmonary disorder (COPD), lung function decline, or any combination thereof.

The invention provides an eCRSwNP nasal endoscopic postoperative treatment method for regulating acidophilic granulocyte activity based on acupuncture, and relates to the technical field of traditional Chinese medicine for preventing and treating nasosinusitis diseases. According to the eCRSwNP nasal endoscopic post-operation treatment method for adjusting the acidophilic granulocyte activity based on acupuncture, accurate adjustment of the acidophilic granulocyte activity is achieved through a synergistic scheme of a nasal endoscopic operation, perioperative drug treatment and standardized acupuncture treatment, the postoperative recurrence rate is reduced, and the nasal symptom and life quality of a patient are improved. Acupuncture point selection, operation specifications, treatment frequency and treatment course of acupuncture are defined, a repeatable and generalizable standardized treatment scheme is formed in combination with strict patient screening standards, a quality control system and ethical guarantee, the technical problems that existing eCRSwNP postoperative treatment is lack of targeted immunoregulation means and the recurrence rate is high are solved, and the therapeutic effect of the eCRSwNP postoperative treatment is improved. And a new clinical path is provided for traditional Chinese medicine intervention on refractory nasosinusitis diseases.

The invention discloses application of tiotropium bromide serving as a medicine for treating eosinophilic nasal polyp. The application comprises application of tiotropium bromide serving as a medicine for treating nasosinusitis with nasal polyp. The invention finds that tiotropium bromide can significantly improve the epithelium remodeling condition of eosinophilic sinusitis with nasal polyp, and can solve the problem of poor effect of treating eosinophilic sinusitis with nasal polyp aiming at T2 type inflammation at present in a manner of treating eosinophilic sinusitis with nasal polyp in a non-inflammatory way.

This invention provides a susceptibility gene for Th2-type asthma, a drug for it, and its application. The susceptibility gene is ALOX15, and the drug is an inhibitor of ALOX15 expression. This invention is the first to discover the relationship between ALOX15 and its main product, 15-HETE-PE, and Th2-type asthma. Inhibition of ALOX15 expression significantly reduces eosinophil expression and the number and percentage of eosinophils in blood and bronchoalveolar lavage fluid. Therefore, specific treatment targeting ALOX15 can serve as a novel treatment for asthma. The drug of this invention effectively reduces eosinophil count in animal and cell experiments, achieving a therapeutic effect for Th2-type asthma. This is a significant advantage compared to some refractory asthma patients whose eosinophil count cannot be reduced to normal levels with existing treatments.

The present invention provides compounds for use in the treatment of pulmonary diseases, particularly asthma, wherein the compounds bind to the cytokines IL-13 and TSLP. The treatment according to the invention is capable of reducing the level of exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo. The treatments of the invention are also capable of reducing eosinophil count, increasing FEV1 and / or reducing airway inflammation.

The invention belongs to the technical field of medicines, and particularly relates to application of vitamin B6 in preparation of a medicine for treating allergic rhinitis. Animal model experiments of allergic rhinitis prove that the vitamin B6 can significantly reduce the proportion of eosinophilic granulocytes in alveolar lavage fluid of model mice and effectively reduce typical allergic behaviors. Preliminary clinical research also shows that the medicine can significantly improve rhinitis symptoms and life quality of patients, and proves that the medicine has an exact treatment effect.

This application discloses a white blood cell detection method for a blood cell analyzer. The method involves using a first detection module to detect white blood cell samples and obtain a white blood cell histogram. The count of basophils is then calculated from the white blood cell histogram. A second detection module then detects the white blood cell samples and obtains a scatter plot showing the two-dimensional distribution of four cell types, yielding the numbers of monocytes, neutrophils, and eosinophils. Finally, the five-part differential ratio of white blood cells is calculated based on the numbers of lymphocytes, monocytes, neutrophils, eosinophils, and basophils. This method can accurately detect various cell types within white blood cells. Furthermore, the calculation method is simple and cost-effective, thus achieving accurate detection results at a low cost.

The invention discloses application of bifidobacterium animalis in relieving respiratory tract allergy symptoms, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the application of the bifidobacterium animalis in relieving the respiratory tract allergy symptoms, the key point of the technical scheme is the application of the bifidobacterium animalis subsp. Lactis BL-5M in relieving the respiratory tract allergy symptoms, and the preservation number of the bifidobacterium animalis subsp. Lactis BL-5M is CGMCC (China General Microbiological Culture Collection Center) No.33449. The medicine can act on the core mechanism of respiratory tract allergy, and the sneezing / cough frequency caused by respiratory tract stimulation reflex is reduced; the lung tissue enlargement mediated by allergic inflammation is relieved; the ratio of eosinophilic granulocytes in bronchoalveolus is reduced; the concentration of proinflammatory factors IL-4 and IL-5 in bronchoalveolus alveolus is reduced; inflammatory cell infiltration around the lung airway wall is reduced; the IgE content in a body circulation system or local tissues is reduced, meanwhile, the diversity of intestinal flora is improved, anti-inflammatory functional flora is accurately enriched, and the allergic asthma is improved in a targeted manner.

The invention relates to application of a palmitoylation modification inhibitor in preparation of a medicine for treating or relieving allergic airway inflammation. The palmitoylation modified inhibitor is applied to the field of treatment of allergic airway inflammatory diseases for the first time. Experimental results show that the inhibitor can significantly inhibit activation of a JAK1 / STAT6 signal channel in vitro and effectively inhibit secretion of Th2 type inflammatory factors such as IL-4 and IL-13 by eosinophilic granulocytes; in animal model research, the palmitoylation modification inhibitor can obviously relieve allergic airway inflammatory reaction of mice, and the allergic airway inflammatory reaction is specifically shown as reduction of the number of eosinophils in bronchoalveolar lavage fluid (BALF), reduction of expression and secretion levels of BALF and lung tissue Th2 type inflammatory factors and obvious relieving of lung inflammation pathological degree. The invention provides a theoretical basis and a potential target for clinically developing a novel therapeutic drug for allergic airway inflammatory diseases in the future.

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

The present disclosure provides a method for treating a subject having eosinophil-associated inflammation, such as severe asthma, comprising administering to the subject a therapeutically effective amount of a composition comprising detoxified Escherichia coli labile toxin (LT).

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof. 20 24 22 02 14 30 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 2 0 2 1 4 3 0 2 0 2 4 S e p